Recipient organisationUniversity of ExeterSource-published name: University of Exeter
Funding£1.6M
PeriodNov 2018 — Oct 2024
In plain English
AI plain-English summary
Scientists cannot watch individual proteins move in real time, and that blind spot limits both fundamental biology and the diagnosis of diseases like Parkinson’s and Alzheimer’s. This fellowship aims to build the first optical instrument that can scan a single protein, detect its vibrations at the nanosecond scale, and map its structure atom by atom—all while the protein sits in solution, doing its job. Current techniques like X-ray crystallography freeze proteins in place; this “molecular scanner” would watch them work. If it succeeds, the device could be shrunk to a coin-sized lab that identifies misfolded proteins from a trace of blood or spinal fluid, with no lengthy preparation. That would give clinicians a rapid diagnostic tool for protein-misfolding diseases—prion disorders, amyloidosis, Parkinson’s, and Alzheimer’s—which together affect more than 47 million people worldwide and cost healthcare systems roughly $604 billion annually (WHO 2017). The same platform could also serve as a test bed for artificial molecular machines, letting engineers observe nano-scale movements in real time. The work is fundamentally curiosity-driven: it tackles one of proteomics’ “holy grails.” But the sensor’s market—analytical instrumentation, worth $48.4 billion globally—suggests that even if the immediate payoff is understanding, the long-term impact on diagnostics and drug development could be substantial.
View original technical description
Despite dramatic advances in x-ray crystallography and electron microscopy, we do not have a way to visualise functional proteins in motion. This fellowship will lead the required breakthroughs and develop the first optical instrument to visualise proteins in real-time and at the level of single molecules. We propose to develop an instrument to probe single proteins in a specific and sensitive manner, while disturbing them as little as possible. The vision is to create a 'molecular scanner' that can characterise an arbitrary protein and its dynamics, a technology that is beyond the current state-of-the-art. Realising this sensor will lead to a new fundamental understanding of how the machinery of life functions. The micro-optical sensor will allow us to analyse proteins in entirely new ways. We will be able to detect proteins specifically, from optically-induced vibrational motions, on portable coin-sized laboratories. The advances I envisage will result in a completely new approach for the analysis and diagnosis of protein-misfolding diseases (proteinopathies) such as prion diseases, Alzheimer's disease, Parkinson's disease, amyloidosis, and a wide range of other disorders. Our sensor platform will be able to contribute to the development of artificial molecular machinery by providing laboratory test beds that observe the motions of nano-machines in real time. We will realise this instrument with optoplasmonic sensors. Optoplasmonic sensors enhance detection signals by reflection-driven circulation of the light. They concentrate the light at the nanoscale where they probe single proteins. We aim to scan the nanoscale light field across a single protein to provide information on the protein structure and its dynamics, resolving protein motions and vibrations at a temporal scale of nanoseconds and at a spatial scale of single bonds and atoms. The optical technique developed in this fellowship will instigate entirely new domains in protein analysis. It will measure and visualise protein structure and its dynamics in-situ, in solution and at surfaces. It will accomplish one of the "holy-grails" of proteomics. Also, this technique can be integrated on a chip, allowing the identification of misfolded proteins from a trace amount of sample, with minimal sample preparation. Thereby it will create new analysis methods, biomarkers and standards for the pharmaceutical and chemical analysis industries. A multitude of industries will be benefitted by the advances of this fellowship, including analytical sensing instrumentation, a $48.4 billion international market. The medical community desperately needs this analysis tool to rapidly detect and characterise intrinsically disordered proteins which cause the debilitating proteinopathies such as Parkinson's and Alzheimer's disease affecting more than 47 million worldwide, at an annual healthcare cost of ~$604 billion (WHO 2017).
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know